JP2021500862A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500862A5
JP2021500862A5 JP2020517456A JP2020517456A JP2021500862A5 JP 2021500862 A5 JP2021500862 A5 JP 2021500862A5 JP 2020517456 A JP2020517456 A JP 2020517456A JP 2020517456 A JP2020517456 A JP 2020517456A JP 2021500862 A5 JP2021500862 A5 JP 2021500862A5
Authority
JP
Japan
Prior art keywords
molecule
polynucleotide
vinylphosphonate
binds
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/054444 external-priority patent/WO2019071028A1/en
Publication of JP2021500862A publication Critical patent/JP2021500862A/ja
Publication of JP2021500862A5 publication Critical patent/JP2021500862A5/ja
Priority to JP2023147876A priority Critical patent/JP7689552B2/ja
Priority to JP2025088275A priority patent/JP2025143247A/ja
Pending legal-status Critical Current

Links

JP2020517456A 2017-10-04 2018-10-04 核酸ポリペプチド組成物およびその使用 Pending JP2021500862A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023147876A JP7689552B2 (ja) 2017-10-04 2023-09-12 核酸ポリペプチド組成物およびその使用
JP2025088275A JP2025143247A (ja) 2017-10-04 2025-05-27 核酸ポリペプチド組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568238P 2017-10-04 2017-10-04
US62/568,238 2017-10-04
PCT/US2018/054444 WO2019071028A1 (en) 2017-10-04 2018-10-04 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023147876A Division JP7689552B2 (ja) 2017-10-04 2023-09-12 核酸ポリペプチド組成物およびその使用

Publications (2)

Publication Number Publication Date
JP2021500862A JP2021500862A (ja) 2021-01-14
JP2021500862A5 true JP2021500862A5 (enExample) 2021-11-04

Family

ID=65995005

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517456A Pending JP2021500862A (ja) 2017-10-04 2018-10-04 核酸ポリペプチド組成物およびその使用
JP2023147876A Active JP7689552B2 (ja) 2017-10-04 2023-09-12 核酸ポリペプチド組成物およびその使用
JP2025088275A Pending JP2025143247A (ja) 2017-10-04 2025-05-27 核酸ポリペプチド組成物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023147876A Active JP7689552B2 (ja) 2017-10-04 2023-09-12 核酸ポリペプチド組成物およびその使用
JP2025088275A Pending JP2025143247A (ja) 2017-10-04 2025-05-27 核酸ポリペプチド組成物およびその使用

Country Status (11)

Country Link
US (4) US11110180B2 (enExample)
EP (1) EP3691657A4 (enExample)
JP (3) JP2021500862A (enExample)
KR (2) KR20250096867A (enExample)
CN (2) CN118267396A (enExample)
AU (2) AU2018346507B2 (enExample)
CA (1) CA3077213A1 (enExample)
MA (1) MA50753A (enExample)
MX (1) MX2020003596A (enExample)
SG (1) SG11202003126VA (enExample)
WO (1) WO2019071028A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
WO2018223081A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
SG11202003126VA (en) 2017-10-04 2020-05-28 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and uses thereof
CN118667812A (zh) 2017-12-06 2024-09-20 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US20210095283A1 (en) * 2018-01-04 2021-04-01 Avidity Biosciences, Inc. Heteroduplex nucleic acid molecules and uses thereof
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
JP7592034B2 (ja) * 2019-06-06 2024-11-29 アビディティー バイオサイエンシーズ,インク. 核酸ポリペプチド組成物およびその使用
KR20220019259A (ko) * 2019-06-06 2022-02-16 어비디티 바이오사이언시스 인크. Una 아미다이트 및 이의 용도
EP4121063A4 (en) 2020-03-19 2024-07-03 Avidity Biosciences, Inc. COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
JP7748962B2 (ja) 2020-03-27 2025-10-03 アビディティー バイオサイエンシーズ,インク. 筋ジストロフィーを処置するための組成物および方法
CN111996193B (zh) * 2020-09-11 2024-02-20 北京键凯科技股份有限公司 一种有效抑制表皮生长因子受体表达的siRNA序列
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20240055874A (ko) 2021-09-16 2024-04-29 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증을 치료하는 조성물 및 방법
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
US12491257B2 (en) 2023-06-27 2025-12-09 Avidity Biosciences, Inc. Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates
US12409230B2 (en) 2023-06-30 2025-09-09 Avidity Biosciences, Inc. Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy
WO2025006955A2 (en) * 2023-06-30 2025-01-02 Ionis Pharmaceuticals, Inc. Cd29 targeted oligonucleotides and uses thereof
CN117122578A (zh) * 2023-08-28 2023-11-28 中国人民解放军空军军医大学 一种负载jph203的改性聚合物纳米粒、其制备方法和应用
CN117820389A (zh) * 2023-12-22 2024-04-05 康羽生命科学技术(苏州)有限公司 5'-O-DMTr-2'-O-MOE-5-甲基尿苷的制备方法
WO2025191337A2 (en) * 2024-03-11 2025-09-18 Synerk Biotech Limited Oligonucleotide terminal phosphate derivatives and method of use

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
DE3687030T2 (de) 1985-03-15 1993-03-11 Eugene Stirchak Stereoregulare polynukleotiden bindende polymere.
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
EP0531597A1 (en) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
AU691306B2 (en) 1994-06-17 1998-05-14 F. Hoffmann-La Roche Ag N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
GB9816575D0 (en) 1998-07-31 1998-09-30 Zeneca Ltd Novel compounds
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DE60216798T2 (de) 2001-10-29 2007-10-18 Mcgill University, Montreal Azyklische linker enthaltende oligonukleotide und deren verwendungen
US20040012626A1 (en) * 2002-07-22 2004-01-22 Brookins Timothy J. Method for creating configurable and customizable web user interfaces
US20040023220A1 (en) 2002-07-23 2004-02-05 Lawrence Greenfield Integrated method for PCR cleanup and oligonucleotide removal
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
ES2645410T3 (es) 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
JP2009542810A (ja) * 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Smad4欠損癌の増殖を阻害するための組成物および方法
BRPI0811170B8 (pt) 2007-05-22 2021-05-25 Arcturus Therapeutics Inc oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
WO2009061941A2 (en) 2007-11-06 2009-05-14 Osmetech Molecular Diagnostics Baseless nucleotide analogues and uses thereof
US20110065774A1 (en) 2008-01-31 2011-03-17 Alnylam Pharmaceuticals Chemically modified oligonucleotides and uses thereof
DK2842575T3 (da) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
AU2009234266B2 (en) 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
DK2344637T4 (en) 2008-10-27 2018-04-23 Biomarin Tech Bv Methods and means for efficiently skipping exon 45 in Duchenne muscular dystrophy pre-mRNA
NZ595955A (en) 2009-04-24 2012-10-26 Prosensa Technologies Bv Oligonucleotide comprising an inosine for treating dmd
BRPI1011269A2 (pt) 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Fc 영역-함유 폴리펩티드, 그것의 사용 방법
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
US9725479B2 (en) * 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
EP3173419A1 (en) * 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
EP2580326A1 (en) 2010-06-11 2013-04-17 Antisense Pharma GmbH Method for selective oligonucleotide modification
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US10100305B2 (en) 2011-07-15 2018-10-16 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス,インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EP2814512A1 (en) 2012-02-16 2014-12-24 UCL Business Plc. Lysosome-cleavable linker
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP2849797B1 (en) 2012-05-15 2019-12-18 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
AU2013336581A1 (en) * 2012-10-26 2015-06-11 Nlife Therapeutics, S.L. Compositions and methods for the treatment of Parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types
JP6358955B2 (ja) 2012-10-31 2018-07-18 武田薬品工業株式会社 新規修飾核酸
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
US9481905B2 (en) 2013-02-19 2016-11-01 Orizhan Bioscience Limited Method of using neutrilized DNA (N-DNA) as surface probe for high throughput detection platform
KR102306490B1 (ko) 2013-03-15 2021-09-28 리제너론 파아마슈티컬스, 인크. 생물학적 활성 분자, 그의 접합체 및 치료 용도
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
US20180104349A9 (en) 2013-04-28 2018-04-19 Gang Qin Novel linker, preparation method, and application thereof
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
BR112016007622A2 (pt) 2013-10-15 2018-01-23 Seattle Genetics, Inc. composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer
EP3610884B1 (en) 2013-11-06 2021-08-18 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
MA39941A (fr) 2014-05-01 2017-03-08 Larry J Smith Procédés et modifications permettant de produire des composés arni simple brin à activité, potentiel et durée d'effet améliorés
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
CN116004624A (zh) 2015-04-03 2023-04-25 马萨诸塞大学 用于靶向亨廷汀mRNA的寡核苷酸化合物
NZ737757A (en) 2015-05-19 2023-07-28 Sarepta Therapeutics Inc Peptide oligonucleotide conjugates
KR20180038465A (ko) * 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스 감염에 대한 rnai 치료법
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
JP2019517991A (ja) 2016-03-01 2019-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 低減したadcpを有するオビヌツズマブ及びリツキシマブ変異体
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CN114736256B (zh) 2016-06-06 2025-09-02 箭头药业股份有限公司 5’-环膦酸酯修饰核苷酸
CN109310765A (zh) 2016-06-20 2019-02-05 领先基因生物技术股份有限公司 抗体-药物偶联物
HUE059718T2 (hu) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok
WO2018129384A1 (en) 2017-01-06 2018-07-12 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
WO2018230624A1 (ja) 2017-06-16 2018-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 修飾核酸モノマー化合物及びオリゴ核酸類縁体
SG11202003126VA (en) 2017-10-04 2020-05-28 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and uses thereof
CN118667812A (zh) 2017-12-06 2024-09-20 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US20210095283A1 (en) 2018-01-04 2021-04-01 Avidity Biosciences, Inc. Heteroduplex nucleic acid molecules and uses thereof
CN109020990A (zh) 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
JP7592034B2 (ja) 2019-06-06 2024-11-29 アビディティー バイオサイエンシーズ,インク. 核酸ポリペプチド組成物およびその使用
KR20220019259A (ko) 2019-06-06 2022-02-16 어비디티 바이오사이언시스 인크. Una 아미다이트 및 이의 용도
US20220395589A1 (en) 2019-10-25 2022-12-15 The Johns Hopkins University Polymeric nanoparticles for intracellular protein delivery

Similar Documents

Publication Publication Date Title
JP2021500862A5 (enExample)
JP2020505330A5 (enExample)
JP2022122928A5 (enExample)
JPWO2018129384A5 (enExample)
IL274906B1 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
JP2023011614A5 (enExample)
JP2021507686A5 (enExample)
JP2021101709A5 (enExample)
JPWO2020132584A5 (enExample)
JPWO2020247782A5 (enExample)
JP2019503394A5 (enExample)
JP2022173349A5 (enExample)
JP2020503049A5 (enExample)
JP2005524393A5 (enExample)
WO2003040366A3 (fr) Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
JP2005517436A5 (enExample)
JP2006502694A5 (enExample)
JP2005517452A5 (enExample)
JP2005517430A5 (enExample)
JP2020522265A5 (enExample)
Shrestha et al. Guanidine bridged nucleic acid (GuNA): an effect of a cationic bridged nucleic acid on DNA binding affinity
JP2005517433A5 (enExample)
RU2022107926A (ru) Олигонуклеотиды, производящие переключение или модулирование сплайсинга пре-рнк и содержащие бициклические каркасные фрагменты, с улучшенными характеристиками для лечения генетических заболеваний
JP2014509511A5 (enExample)
JP2020512843A5 (enExample)